|Bid||54.51 x 900|
|Ask||55.33 x 1200|
|Day's range||52.83 - 55.67|
|52-week range||44.45 - 151.80|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||72.64|
DGAP-News: CureVac / Key word(s): Alliance14.09.2021 / 13:19 The issuer is solely responsible for the content of this announcement.CureVac Streamlines European Network for mRNA Product Manufacturing CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review with EMA Contracts with manufacturing partners WACKER and Celonic terminated; Rentschler Biopharma and Nov
GlaxoSmithKline (GSK) and SK bioscience begin a phase III study on GBP510, the latter's COVID-19 vaccine candidate. The study will compare GBP510 against AstraZeneca's COVID-19 vaccine.
CureVac (NASDAQ: CVAC) recently announced that Boehringer Ingelheim terminated a partnership on a messenger RNA lung cancer vaccine program. In this Motley Fool Live video recorded on Aug. 18, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not this canceled deal spells trouble for other mRNA cancer vaccines in development.